Sixteen patients with relapsed nomHodgkin's lymphoma underwent autologous bone marrow transplantation and infusion of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF). Treatment consisted of involved-field radiotherapy, cyclophosphamide 60 mglkgld intravenously (IV) for 2 days, and fractionated total body irradiation (1,200 cGy). Autologous bone marrow was thawed and infused IV, followed 3 hours later by the first infusion of IV rhGM-CSF 11 pglkgld over 4 hours. Infusions of rhGM-CSF were continued daily until either both neutrophil count exceeded 1,5001pL and platelet count exceeded 50.0001pL. or until 30 days after marrow re-infusion. Toxicities encountered were mild and included fever, chills, hypertension, alopecia, rash, diarrhea, stomatitis, myalgias, and synovial (knee) effusions. Neutrophil recovery greater than 5OOlpL occurred a median of 14 days (range, 9 t o 30 days) after marrow infusion, significantly earlier than in a comparable group of historic controls who recovered counts at a median time of 20 days (range, 12 t o 51 days) (P = .00002). Median time t o self-sustaining platelet counts greater than 20,0001pL N VITRO ANALYSIS of the control of hematopoiesis I has identified a group of glycoproteins that control the proliferation, differentiation, and survival of the various hematopoietic blood cell lineages.',' Although originally described in the murine system, the complementary DNA (cDNA) for each of the human analogues has been cloned and expressed in bacterial, yeast, or mammalian systems. Several of these recombinant hematopoietic or colonystimulating factors have been produced, purified, and used successfully to stimulate recovery of peripheral blood cell counts in a variety of condition^.'^^ We undertook this phase I1 trial in the cooperative oncology group setting to assess colony-forming unit granulocyte-macrophage (CFU-OM) progenitors per kg. Stem cell progenitors CFU-GM, CFUgranulocyte, erythroid, monocyte, megakaryocyte (CFU-GEMM), and burst-forming unit-erythroid (BFU-E) were detected in the bone marrow as early as 7 days after marrow re-infusion, and increased in proportion t o peripheral blood counts, but by 30 t o 60 days still remained much lower than before transplant. Neutrophils transiently decreased in 13 of 16 patients (median decrease, 42%) within 24 t o 72 hours of discontinuing rhGM-CSF infusions. These data suggest that rhGM-CSF therapy enhances neutrophil recovery by forcing stem cells to produce mature elements at an enhanced rate but may not affect marrow stem cell and early progenitor population sizes. 0 1991 b y The American Society of Hematology.
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the safety and efficacy of infusions of a mammalianexpressed recombinant human hematopoietic growth factor granulocyte-macrophage colony-stimulating factor (rhGM-CSF) during a total body irradiation-containing regimen, and to examine specific effects on bone marrow (BM) and blood progenitors.
PATIENTS AND METHODS
Patients 15 to 60 years of age with histologically confirmed non-Hodgkin's lymphoma' in relapse were eligible to participate as part of protocol EST P-Z488 of the Eastern Cooperative Oncology Group (ECOG)! Pretreatment evaluation included history and physical examination; chest radiograph; pulmonary function tests; electrocardiogram; radionuclide gated blood-pool scanning; measurement of 24-hour urine creatinine clearance; and external imaging tests for determination of tumor size and location. Patients with an ECOG performance status of greater than 1, central nervous system metastases, serum creatinine greater than 1.5 mg/dL, 24-hour creatinine clearance less than 60 mllmin, carbon monoxide lung diffusion capacity less than 60% of predicted, cardiac ejection fraction less than 50% of predicted, and serum asparate aminotransferase or serum total bilirubin greater than twice normal were excluded from participation. In addition, patients shown to have lymphoma involving the BM (on routine histologic examination) and patients who received previous extensive local radiation (eg, mantle or large mediastinal configuration, pelvic radiation therapy, etc) were ineligible for this trial. Patients gave written informed consent, and the protocol was approved by the Institutional Review Board for Human Investigation at each participating institution.
BM was aspirated under general or regional anesthesia at least 4 weeks since exposure to cytotoxic therapy, except in the case of treatment with nitrosoureas, in which case at least 6 weeks must have elapsed. BM was cryopreserved with a controlled-rate liquid nitrogen freezing apparatus using previously published methods.' BM was not treated in vitro with
Patientpopulation.
BM transplant protocol. chemicals or monoclonal antibodies (MoAbs) (invitro purging) but was frozen in a final concentration of 10% dimethylsulfoxide and 10% irradiated autologous plasma, and was stored in the liquid phase of a liquid nitrogen refrigerator (-196°C) until used. All patients received a multi-lumen central venous catheter for venous access. The intensive chemo-radiation therapy or conditioning regimen has been reported previously.' Briefly, treatment consisted of 1,200 to 2,000 cGy involved-field radiation therapy days T-17 through T-6 (eg, 17 through 6 days before marrow infusion) to previously bulky (> 5 cm diameter) or active disease sites in 10 fractions over 14 days, intravenous (IV) cyclophosphamide 60 mgkgld on days T-5 and T-4, and 1,200 cGy fractionated total body irradiation (200 cGy twice daily 6 to 10 hours apart at 20 to 30 cGy/min) on days T-3 through T-1. Through one dedicated lumen of the central venous catheter, intravenous therapy with rhGM-CSF at a dose of 11 pg/kg/d was begun 3 hours after completion of marrow infusion (day T-0). rhGM-CSF was administered IV daily thereafter over 4 hours until either (1) recovery of both neutrophil count (> 1,500/pL) and platelet count (>50,00O/pL, untransfused) occurred, or (2) colony-stimulating factor therapy was administered for a total of 30 days.
Complete blood counts, measurements of serum electrolytes, and serum tests of liver and renal function were obtained at least thrice weekly. Patients were treated in single hospital rooms equipped with high-efficiency particulate air filters and placed on a diet low in bacterial and fungal content. The hematocrit was maintained in the 25% to 30% range by transfusion of packed, irradiated red blood cells, and the platelet count was maintained above 2O,OOO/pL by platelet concentrate transfusions. All blood products received 1,500 to 3,000 cGy of irradiation. Parenteral alimentation and broad-spectrum antibiotic support were used as clinically indicated. Toxicity grading was according to the Common Toxicity Criteria of the National Cancer Institute.
A historic control group consisted of our previously published multi-institutional experience; 52 patients received involved-field radiation therapy, intravenous cyclophosphamide, and fractionated total body irradiation with autologous BM support.' Of these patients, 47 patients remained alive at least 30 days after marrow re-infusion and were used to construct the historical data for this comparison.
Complementary DNA encoding GM-CSF was cloned and expressed by Genetics Institute (Cambridge, MA)? Glycosylated rhGM-CSF was formulated as a lyophilized powder by Sandoz Pharmaceuticals (Basel, Switzerland), and was supplied by Sandoz Research Institutes (East Hanover, NJ). The specific activity of rhGM-CSF, as measured by 'H-thymidine uptake of peripheral blood from patients with untreated chronic myelogenous leukemia (CML), was 5.4 x lo6 IU/mg of glycoprotein (8.0 x lo6 CML units/mg nonglycosylated protein). rhGM-CSF was reconstituted in sterile water, and dose was expressed in terms of protein weight by amino acid content.
Immediately before beginning involved-field radiation therapy, 2.5 mL BM aspirates from the posterior iliac crests and 20 mL peripheral blood samples were collected for hematopoietic stem cell assays. Thereafter, 20 mL blood samples were collected twice weekly beginning 1 week before transplant and continued until discharge; BM aspirates (2.5 mL) were performed weekly beginning the day of BM re-infusion (day of BM transplantation, ie, day T-0). All samples were collected in sodium heparin without preservatives at a final concentration of 30 U/mL (Sigma Chemicals, St Louis, MO). BM and peripheral blood mononuclear cells were prepared by FicollHypaque as previously described." BM cells were plated at 2 x lo5 cells/mL and blood cells at 5 X 105 cells/mL as follows": cells were suspended in a mixture of Iscove's modified Dulbecco's medium Historic controls.
rhGM-CSF.
In vitro peripheral blood and BM cultures. kindly provided by Dr E. Liehl, Sandoz Forschungsinstitut, Vienna, Austria). Hematopoietic stem cells were plated in 1 mL aliquots in triplicate 35" gridded plastic plates at 3 7 T , 5% carbon dioxide for 14 days. The number of erythroid burst-forming units (BFU-E), granulocyte-macrophage colony-forming units (CFU-GM), and mixed granulocyte-erythroid-macrophage-megakaryocyte colonyforming units (CFU-GEMM) were counted." The variation between plates in CFU number was less than 12%. Data were recorded as the mean of triplicate values for individual assays and as mean f SD for the group as a whole.
The Pet0 Wilcoxon test was used to compare recovery of neutrophil and platelet count between the study population and historic controls. Linear regression analysis was used to compare hematopoietic variables before and after marrow transplant.
Statistical methods.

RESULTS
Patient charactektics before initiating transplant conditioning regimen.
Sixteen patients entered this study between January 1989 and February 1990. These patients were treated at the Ireland Cancer Center, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH; Shands Hospital, University of Florida, Gainesville; and the Hospital of the University of Pennsylvania, Philadelphia.
All patients treated on this protocol either had relapsed lymphoma or had tumor resistant to cytotoxic drug therapy. Ten patients previously were exposed to one of several conventional combination chemotherapies, five patients heretofore were treated with two differing regimens, and one patient eventually failed three different chemotherapy combinations. Before beginning cyclophosphamide and total body irradiation therapy, all patients received involvedfield radiation. Thirteen of 16 patients were exposed to at least one radiation treatment field that involved a large marrow-bearing area, such as the entire mediastinum, entire para-aortic and celiac region, or whole pelvis or whole abdominal field. Other patient characteristics are shown in Table 1 .
Patients received a median of 26 days rhGM-CSF therapy (range, 13 to 30 days). Recovery to neutrophils greater than 500/pL was significantly faster (median, 14 days; range, 9 to 30 days) than in controls (median, 20 days; range, 12 to 51 days) (P = .00002, Pet0 Wilcoxon test). Time to self-sustaining platelet count greater than 20,00O/pL was 23.5 days in the rhGM-CSF group (range; 12 to 100 days) comparable with 26 days in the control group (range, 7 to 149 days) (P = .38, Pet0 Wilcoxon test). This is not a randomized comparison and the tests have not been adjusted for differences in patient characteristics between the two groups that might be relevant to hematopoietic reconstitution. However, even with this caution, it is clear that rhGM-CSF therapy resulted in a significant shortening of
Eficacy.
For personal use only. on October 23, 2017. by guest www.bloodjournal.org From the time to neutrophil recovery. Patients were hospitalized for a median of 37 days, which ranged from 27 to 57 days. During the hospital stay, a median of 8 U of red blood cells (range, 4 to 25 U) were infused, and a median of 72 U of platelets (range, 12 to 217 U) were transfused. Data from the historic control group regarding duration of hospital stay and transfusion exposure are not available for comparison. Cessation of rhGM-CSF was accompanied by a transient but marked decrease in granulocyte count in most patients. In 13 of 16 patients the neutrophil count decreased a median of 42% (range, 10% to 73%) within 72 hours of discontinuing rhGM-CSF therapy. Neutrophil count did not decrease below 500ipL and no patients developed infection during this temporary decrease in neutrophils.
Despite the use of rhGM-CSF infusions for up to 30 days (median, 26 days), infusions of rhGM-CSF therapy were well-tolerated, even in some patients who had already recovered normal neutrophil count but not adequate platelet count. Mild to moderate reversible toxicities were noted in most patients, but rhGM-CSF infusions were not discontinued because of toxicity in any patients. Three patients developed grade 2 myalgias, and two patients developed synovial (knee) effusions. These effusions occurred during the first week of rhGM-CSF therapy, were transudates on examination, and resolved within 1 week without specific therapy despite continuing rhGM-CSF infusion. Three patients experienced unexplained weight gain (grade 1 in two patients and grade 2 in one patient). One patient developed a marked increase (grade 2) in
Toxicity.
systolic blood pressure in association with rhGM-CSF infusions.
Other toxic effects observed in our patients included mucositis, diarrhea, neutropenia, fever, and infection, all of which are recognized concomitants of the BM transplant preparative regimen! Twelve patients experienced grade 1 or 2 mucositis and one patient had grade 3 mucositis. Twelve patients developed diarrhea usually grade 1 or 2, but one patient each experienced grade 3 and grade 4 toxicity. In the historic control group, the frequency was similar but the severity worse?
All patients developed neutropenic fever and required the institution of broad-spectrum parenteral antibacterial agents. Patients had a median of 8.5 days of fever defined as oral temperature greater than 38°C (range, 2 to 26 days), and combination parenteral antibacterial agents therapy was administered for a median of 14.5 days (range, 8 to 32 days). In addition, 12 of 16 patients received amphotericin B therapy administered in empiric fashion for persistent neutropenic fever despite the use of broad-spectrum antibacterial agents. The amphotericin B cumulative dose administered ranged from 150 to 930 mg (median, 480 mg), which was administered over a median 10-day period (range, 3 to 26 days).
Only one patient developed a bacteremia, due to a Staphylococcus epidemidis central venous catheter exit site infection. This infection occurred the day of marrow reinfusion when the neutrophil count was 65O/pL, and the infection resolved with the use of parenteral antibacterial agents. Another patient developed a mild, transient Giardia Patients received a median of 2.5 x 10' nucleated BM cellskg (range, 1.1 to 2.8 x lo8 cellskg), similar to the historic control group in which a median number of nucleated marrow cells reinfused was 2.0 x 10' cellskg (range, 1.0 to 8.0 x 10' cellskg). Ten patients were evaluated for circulating and BM hematopoietic stem cells, CFU-GM and BFU-E, before and after preparative chemo-radiation therapy, autologous BM re-infusion, and administration of GM-CSF therapy. Changes in hematopoietic stem cells were compared with the duration of neutropenia and with evidence of late BM regeneration. This group of 10 patients received a median of 26 (range, 13 to 30) days of GM-CSF and experienced a median of 14 (range, 9 to 30) days of less than 500 neutrophilsiyl ( Table 1 ). The median number of CFU-GM progenitors infused was 11.4 (range, 4.4 to 20.2) x 104/kg and of BFU-E infused was 14.4 (range, 10.9
All patients showed early regeneration of hematopoietic precursors in the BM between days 10 and 22 after transplantation ( Table 2) . During this early regeneration phase, the recovery of BM stem cells reached a median of 54% (range, 22% to 200%) of pretreatment CFU-GM and a median of 19% (range, 5% to 83%) of pretreatment BFU-E.
Hematopoietic reconstitution.
to 20.9) x 104kg.
Peripheral blood stem cells also were monitored in these patients (Fig 1) . Blood progenitor cells (BFU-E and CFU-GM) decreased promptly after cytotoxic therapy and persisted at levels of 20% to 40% of pretreatment values after the transplant.
Two patterns of hematopoietic recovery are shown (Fig  2) . Patient no. 48809 (Fig 2A and D) demonstrated good early white blood cell recovery, but maintained a low neutrophil count for up to 90 days after marrow reinfusion. Early CFU-GM are observed in the marrow, but late progenitor cell blood concentrations are very low. The second, more common pattern is represented by patients no. 48811 (Fig 2B and E) and no. 48813 (Fig 2C and F) . These patients have adequate and sustained regeneration of both peripheral blood neutrophil count and hematopoietic recovery in the BM.
Sixty to 90 days after marrow re-infusion only three of nine patients showed full regeneration (to pretreatment levels) of CFU-GM concentrations in BM and only one patient had full regeneration of BFU-E concentrations. Three patients had less than 25% of pretreatment CFU-GM concentrations and five patients had BFU-E of less than 25% pretreatment values. The two patients with the most severe late neutropenia had the lowest numbers of CFU-GM and BFU-E in their BM. Between 60 and 90 days after transplant, three patients maintained moderate neutropenia in the range of 396 to 1,150 neutrophilslyl. However, these three patients may have benefitted from GM-CSF levels of CFU-GM and BFU-E in the BM, whereas those with the least recovery of neutrophil counts had the lowest levels of BFU-E in the BM and tended to have the lowest levels of BM CFU-GM as well.
There was a statistically significant correlation between the pretreatment BFU-E BM concentration and the "late" (ie, 60 days after transplant) CFU-GM (but not BFU-E) concentration in the marrow (I' = S02, P < .05, linear regression analysis). As might be expected, a correlation was noted between the number of days of rhGM-CSF therapy and days until recovery of neutrophils in excess of 500/pL (? = .472, P < .05, linear regression analysis). However, no correlation was noted between the number of CFU-GM per kilogram or BFU-E per kilogram infused treatment because the early phase of BM recovery in these three patients in terms of BM CFU-GM and blood neutrophil counts was similar to those who had good evidence of late hematopoietic recovery. Of note, these three patients had the lowest levels of BM BFU-E during the period on GM-CSF therapy ( Table 2) . Thus, those patients with the best late recovery in neutrophil counts had the highest * UI'NJXXO'I 
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tion between the length of GM-CSF treatment and either the early or late increase in stem cells present in the BM, nor was there a correlation between the time to reach an absolute neutrophil count of 500/pL and either the early or late regeneration of CFU-GM. These observations suggest that GM-CSF therapy is able to promote hematopoiesis as well as encourage early production of neutrophils even in patients who later show long-term deficiencies in hematopoiesis.
Most patients had a decrease in both peripheral blood neutrophil count and CFU-GM concentrations in the BM immediately after withdrawal of GM-CSF therapy. This decline was particularly severe in those patients with low 
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neutrophil counts 60 to 90 days after transplant. During GM-CSF treatment there were often circulating BFU-E and CFU-GM stem cells at levels that were 30% to 50% of those seen before treatment (Fig 1) . However, most patients recovered less than 50% of the numbers of BFU-E or CFU-GM cells in the peripheral blood 60 to 90 days after transplant. In no instance was the GM-CSF withdrawalrelated decrease in blood counts or the later evidence of inadequate BM reserve associated with evidence of infection.
Eight of the 16 patients undergoing marrow transplantation and rhGM-CSF therapy achieved complete remission, the duration ranging from 4 to 21+ (median, 12+) months. Five patients remain in continued complete remission. These data are similar to our previously published experiences using this regimen in the absence of rhGM-CSF therapy?
Antitumor effect.
DISCUSSION
Infusion of hematopoietic stem cells (eg, BM or peripheral stem cell transplantation) after high-dose chemoradiation therapy is an effective therapeutic modality for a variety of malignant and non-malignant condition^.^^-'^ Despite the use of intensive supportive care, the morbidity and mortality of transplantation still remain high. For example, one group reported that in 143 consecutive autologous marrow transplants, 83 bacteremias (in 72 patients) occurred.I8 Hematopoietic growth factor infusions have been administered to a number of patients undergoing transplantation, and, in the course of these phase I and I1 trials, morbidity appears to be less in some patient^.'^.'^ All trials used rG-CSF or rGM-CSF therapy, except one2' in which human urinary colony-stimulating factor was infused.
Our study involved a number of unique aspects compared with other published trials. First, our patients received involved-field radiation, which can cause additional significant damage to the micro-environment and retard engraftment. All patients except one received at the least mediastinal irradiation, paraaortic irradiation, or both. Second, we documented both the number of CFU-GM infused as well as in vivo recovery of these progenitors. Finally, this trial examined the early as well as late hematologic and marrow recovery.
Neutrophil count recovery (> 500/pL) was prompt in most patients after receiving the ablative total body radiation-containing regimen. While one patient took 30 days for adequate granulocyte recovery to take place, most patients recovered this component of marrow function within 3 weeks after receiving infusions of thawed, cryopreserved marrow and rhGM-CSF infusions.
Patients who have received infusions of G-CSF or GM-CSF after marrow transplant appear to have a marked decrease in documented infection^.'^^^^^^ This effect is thought to reflect both earlier recovery of neutrophil count as well as enhancement of neutrophil and monocyte funct i~n .~~ GM-CSF enhances phagocytic ability of myeloid cells and increases cytotoxic function once phagocytosis has been a~hieved.'~ We noted only one bacteremia, and a total of two infections in this intensively treated patient group.
As in other trials, no discernable effects could be observed on recovery of platelet count in our patients. However, Nemunaitis et alZ7 did observe that their study group became independent of platelet transfusions about 19 days (mean) after transplant, compared with 38 days in the historic control group. It is unclear why these effects on platelet recovery occurred.
This study shows that decreased levels of CFU-GM and BFU-E are present in the BM 60 to 90 days after marrow transplant and that circulating levels of BFU-E are markedly lower than the pretransplant values. GM-CSF infusions allow earlier recovery of neutrophil counts and generation of both circulating and BM-derived CFU-GM and BFU-E. Most importantly, GM-CSF appears to enable patients with profound hematopoietic defects to regenerate neutrophils even though these patients later have evidepce of poor hematopoietic recovery. However, in no instance was this level of hematopoiesis life-threatening or associated with late morbidity. The duration of GM-CSF in this study did not seem to influence the course of later hematopoietic recovery. Furthermore, the recovery of CFU-GM was better than BFU-E both early and late after transplant.
It is possible, of course, that pharmacologic doses of rhGM-CSF administered during the BM regeneration period may have forced premature differentiation of progenitors, depleting this pool and causing a persistent deficit in both CFU-GM and BFU-E at 60 to 90 days after BM infusion. This postulate could explain why a number of patients had a profound reduction in the concentration of stem cells at times remote to the transplant. Detailed accounting of stem cell concentrations are not available from the historic controls and, thus, a direct comparison is not possible. While the issue of stem cell depletion by growth factors remains of theoretical concern, there is no direct clinical evidence to indicate that it is a therapeutic issue.
Our progenitor data are in contrast to those reported by Kurtzberg et al,m who reported in preliminary fashion that continuous infusion rhGM-CSF resulted in increases in CFU-GM that were not sustained, and BFU-E levels were depressed throughout the transplant period. These investigators did not report peripheral blood progenitor data. These differing results could be explained by technical differences in performing the assays, as well as the fact that our study used total body irradiation, and we infused the rhGM-CSF 4 hours daily, but for a longer duration after the transplant.
GM-CSF has been shown to stimulate myeloid leukemic blast cell proliferation in v i t r~.~~,~' No obvious stimulation of lymphoma was noted, although one patient (no. 48810) developed a secondary neoplasm (T-cell non-Hodgkin's lymphoma 3 months after transplant for a B-cell lymphoma). In a prospective randomized, placebo-controlled trial of 60 patients, Vose et a133 did not observe that GM-CSF promoted lymphoma progression when administered after high-dose chemotherapy and autologous stem cell transplantation. The anticancer effectiveness of the involved-field radiotherapy, cyclophosphamide, and fractionFor personal use only. on October 23, 2017. by guest www.bloodjournal.org From 836 LAZARUSETAL ated total body irradiation regimen plus rhGM-CSF therapy in this trial was similar to our previously published report. ' Discontinuing growth factor infusions in 13 of 16 of our patients was associated with a marked decrease (median 42%) in granulocyte count. Nemunaitis et aIz7 similarly reported that discontinuing growth factor infusions was associated in four of eight patients with a mean decrease in neutrophil count of 35% (range, 4% to 63%) within 24 to 72 hours after stopping GM-CSF therapy (range, 4% to 63%). Brandt et a126 (using GM-CSF) and Taylor et a124 (using G-CSF) noted the same effect. While our data indicate that rhGM-CSF infusions have little or no effect on marrow stem cells and early progenitors, our in vitro marrow progenitor assays suggest that the growth factors are forcing stem cells to produce mature elements at an enhanced rate, hence a drop in granulocyte count when the recombinant colony-stimulating factor is withdrawn. Similarly, Lord et a134 showed that another hematopoietic growth factor, rG-CSF, temporarily accelerated early marrow progenitor maturation into neutrophils from a time period of 5 days to 1 day. rhGM-CSF is able to stimulate early neutrophil recovery even in those patients who exhibit defects in later tests of in vitro hematopoiesis. Our data also support the results of Blazar et al,23 who examined GM-CSF therapy after reinfusion of autologous BM purged in vitro. They noted efficacy of GM-CSF only when at least 1.2 x lo4 CFU-GM progenitors/kg were infused. Their patients who received infusions containing lower numbers did not appear to benefit from GM-CSF therapy. Our data showed a relatively uniform number of CFU-GM per kilogram infused (median, 11.4 x lo4; range, 4.4 to 20.2 x 10 4), in part due to the fact that ex vivo purging was not used and most patients experienced prompt marrow recovery.
Previous phase I and I1 trials reported that most patients developed mild to moderate, self-limited toxicities attributable to recombinant hematopoietic growth factors. We observed a similar toxicity profile, and most patients experienced mild to moderate side effects such as fever, myalgias, and diarrhea. Effects previously reported at low or intermediate dose such as bone pain3' or adverse effects noted at high doses, such as pleural or pericardial effusions, were not observed during this triaLZ6 On the other hand, we observed synovial effusions in two patients, a previously unreported toxicity.
Recently, two randomized, placebo-controlled trials prospectively evaluating the efficacy of rhGM-CSF in autologous BM transplantation were presented in preliminary Both trials showed reduction in transplantrelated morbidity and earlier hospital discharge. Additional studies using recombinant hematopoietic growth factors after autologous BM transplantation are warranted to define the optimum dose and schedule of these therapeutic agents.
